HT-6184
Sponsors
Halia Therapeutics, Inc.
Conditions
Anemia in Myelodysplastic SyndromesDiabetes Mellitus, Type 2Myelodysplastic SyndromeNormal Healthy SubjectsObesityPain
Phase 1
Phase 2
Evaluating Ability of HT-6184 to Reduce Inflammation and Pain After Third Molar Extraction
CompletedNCT06241742
Start: 2024-02-12End: 2024-04-30Updated: 2025-03-30
A Phase 2a Study of HT-6184 in Subjects With IPSS-R Very Low, Low or Intermediate Risk MDS and Anemia
Active, not recruitingNCT07052006
Start: 2023-12-09End: 2026-10-15Updated: 2026-09-17
A Ph2 Study to Evaluate the Safety, Efficacy and Tolerability of HT-6184 and Semaglutide in Obese Participants With T2DM
WithdrawnNCT07172867
Start: 2026-01-06End: 2026-01-23Updated: 2026-02-25